Novel mutations in the gene encoding ATP-binding cassette 1 in four tangier disease kindreds.
暂无分享,去创建一个
L. M. Thurston | P. van Eerdewegh | M. Freeman | M. FitzGerald | J. Ordovás | E. Schaefer | B. Weiffenbach | B. Eustace | J. Dupuis | G. O'neill | M. Brousseau | G. Eberhart | R. H. Brown | A. Goldkamp | D. Yasek-McKenna | J. Gu | J. Gu | P. Eerdewegh | Brenda K. Eustace | J. Ordovás | A. L. Goldkamp | Diane Yasek-McKenna | G. P. Eberhart | Robert H. Brown
[1] J. Sambrook,et al. Molecular Cloning: A Laboratory Manual , 2001 .
[2] P. Denéfle,et al. Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[3] A. Vaughan,et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. , 1999, The Journal of clinical investigation.
[4] J. Piette,et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1 , 1999, Nature Genetics.
[5] T. Langmann,et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease , 1999, Nature Genetics.
[6] C. Sensen,et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency , 1999, Nature Genetics.
[7] T. Langmann,et al. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. , 1999, Biochemical and biophysical research communications.
[8] G. Assmann,et al. Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy , 1998, Nature Genetics.
[9] E. Schneider,et al. ATP-binding-cassette (ABC) transport systems: functional and structural aspects of the ATP-hydrolyzing subunits/domains. , 1998, FEMS microbiology reviews.
[10] M. Freeman,et al. Decreased cholesterol efflux from fibroblasts of a patient without Tangier disease, but with markedly reduced high density lipoprotein cholesterol levels. , 1998, The Journal of clinical endocrinology and metabolism.
[11] G. Torpier,et al. High-density-lipoprotein subfraction 3 interaction with glycosylphosphatidylinositol-anchored proteins. , 1997, The Biochemical journal.
[12] H. Brewer,et al. Decreased reverse cholesterol transport from Tangier disease fibroblasts. Acceptor specificity and effect of brefeldin on lipid efflux. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[13] K. Simons,et al. Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol microdomains. , 1997, Current opinion in cell biology.
[14] B. Verrier,et al. ABC1, an ATP Binding Cassette Transporter Required for Phagocytosis of Apoptotic Cells, Generates a Regulated Anion Flux after Expression in Xenopus laevis Oocytes* , 1997, The Journal of Biological Chemistry.
[15] A. Mendez,et al. Apolipoprotein-mediated cellular cholesterol and phospholipid efflux depend on a functional Golgi apparatus. , 1996, Journal of lipid research.
[16] G. Assmann,et al. Defective regulation of phosphatidylcholine-specific phospholipases C and D in a kindred with Tangier disease. Evidence for the involvement of phosphatidylcholine breakdown in HDL-mediated cholesterol efflux mechanisms. , 1996, The Journal of clinical investigation.
[17] Piet Borst,et al. MDR1 P-Glycoprotein Is a Lipid Translocase of Broad Specificity, While MDR3 P-Glycoprotein Specifically Translocates Phosphatidylcholine , 1996, Cell.
[18] K Lange,et al. Descent graphs in pedigree analysis: applications to haplotyping, location scores, and marker-sharing statistics. , 1996, American journal of human genetics.
[19] P. Pedersen,et al. The First Nucleotide Binding Fold of the Cystic Fibrosis Transmembrane Conductance Regulator Can Function as an Active ATPase (*) , 1995, The Journal of Biological Chemistry.
[20] C. Higgins,et al. The ABC of channel regulation , 1995, Cell.
[21] G. Schmitz,et al. Activation of phosphatidylinositol-specific phospholipase C in response to HDL3 and LDL is markedly reduced in cultured fibroblasts from Tangier patients. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[22] G. Francis,et al. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier Disease. , 1995, The Journal of clinical investigation.
[23] G. Rogler,et al. HDL-mediated efflux of intracellular cholesterol is impaired in fibroblasts from Tangier disease patients. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[24] J. Bryan,et al. Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. , 1995, Science.
[25] G. Assmann,et al. The high density lipoprotein- and apolipoprotein A-I-induced mobilization of cellular cholesterol is impaired in fibroblasts from Tangier disease subjects. , 1994, Biochemical and biophysical research communications.
[26] R. Lees,et al. Homozygous Tangier disease and cardiovascular disease. , 1994, Atherosclerosis.
[27] P. Wilson,et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. , 1994, Journal of lipid research.
[28] F. Denizot,et al. Cloning of two novel ABC transporters mapping on human chromosome 9. , 1994, Genomics.
[29] V. Ling,et al. ATPase activity of purified and reconstituted P-glycoprotein from Chinese hamster ovary cells. , 1994, The Journal of biological chemistry.
[30] M. Welsh,et al. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis , 1993, Cell.
[31] C. Higgins,et al. ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.
[32] C. Higgins,et al. Separation of drug transport and chloride channel functions of the human multidrug resistance P-glycoprotein , 1992, Cell.
[33] P. Greengard,et al. Phosphorylation of the cystic fibrosis transmembrane conductance regulator. , 1992, The Journal of biological chemistry.
[34] R. Boucher,et al. Biochemical characterization of the cystic fibrosis transmembrane conductance regulator in normal and cystic fibrosis epithelial cells. , 1992, The Journal of biological chemistry.
[35] A. Garner,et al. The cornea in familial high density lipoprotein deficiency, tangier disease , 1991 .
[36] A. Mendez,et al. Protein kinase C as a mediator of high density lipoprotein receptor-dependent efflux of intracellular cholesterol. , 1991, The Journal of biological chemistry.
[37] G. Ames,et al. The membrane-bound proteins of periplasmic permeases form a complex. Identification of the histidine permease HisQMP complex. , 1991, The Journal of biological chemistry.
[38] J. Slotte,et al. High density lipoprotein apolipoproteins mediate removal of sterol from intracellular pools but not from plasma membranes of cholesterol-loaded fibroblasts. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.
[39] G. Schmitz,et al. Dysregulation of lipid metabolism in Tangier monocyte-derived macrophages. , 1990, Arteriosclerosis.
[40] S. Akiyama,et al. Cytoplasmic orientation and two-domain structure of the multidrug transporter, P-glycoprotein, demonstrated with sequence-specific antibodies. , 1989, The Journal of biological chemistry.
[41] J. Breslow,et al. Sequence and expression of Tangier apoA-I gene. , 1988, European journal of biochemistry.
[42] R. Gregg,et al. In vivo metabolism of proapolipoprotein A-I in Tangier disease. , 1987, The Journal of clinical investigation.
[43] H. Brewer,et al. Tangier disease. The complete mRNA sequence encoding for preproapo-A-I. , 1985, The Journal of biological chemistry.
[44] J. Ott,et al. Multilocus linkage analysis in humans: detection of linkage and estimation of recombination. , 1985, American journal of human genetics.
[45] E. Schaefer. Clinical, biochemical, and genetic features in familial disorders of high density lipoprotein deficiency. , 1984, Arteriosclerosis.
[46] J. Albers,et al. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. , 1982, Clinical chemistry.
[47] H. Brewer,et al. Metabolism of high density lipoprotein subfractions and constituents in Tangier disease following the infusion of high density lipoproteins. , 1981, Journal of lipid research.
[48] H. Brewer,et al. Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease). , 1980, Annals of internal medicine.
[49] C. Blum,et al. Metabolism of high-density lipoprotein apolipoproteins in Tangier disease. , 1978, The New England journal of medicine.
[50] Oliver H. Lowry,et al. Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.
[51] P. Wilson,et al. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. , 1996, Clinical chemistry.
[52] Ion Channels and Genetic Diseases. Proceedings of the Society of General Physiologists 48th Annual Symposium. Woods Hole, Massachusetts, 7-11 September 1994. , 1995, Society of General Physiologists series.
[53] I. Pastan,et al. Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.
[54] M. Boehnke,et al. Allele frequency estimation from data on relatives. , 1991, American journal of human genetics.
[55] L. Tsui,et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.
[56] G. Assmann,et al. Interaction of Tangier lipoproteins with cholesteryl ester-laden mouse peritoneal macrophages. , 1987, Journal of lipid research.